ACC 2021 Highlights: Drugs and Alcohol ACC 2021 Highlights: Drugs and Alcohol
Aspirin dosing, alcohol and atrial fibrillation, dual vs mono antiplatelet therapy post PCI, and sacubitril/valsartan post MI are among the drug highlights from ACC 2021.theheart.org on Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

LIFE: ARNI Does Not Best Valsartan in Advanced Heart Failure LIFE: ARNI Does Not Best Valsartan in Advanced Heart Failure
' We were surprised and disappointed and stared at the data for a long time, partly in disbelief,'said the lead investigator. However, a lot more is now known about this'remarkable class of drugs. 'Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - June 8, 2021 Category: Primary Care Tags: Cardiology News Source Type: news

Sacubitril/Valsartan: Trending Toward PARADISE Post MI? Sacubitril/Valsartan: Trending Toward PARADISE Post MI?
PARADISE-MI fell short on statistical significance but investigator Marc Pfeffer is persuaded by trends for clinical benefit. The key:'Start the drug early and sustain it,'he tells Ileana Pina.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 19, 2021 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Sacubitril/valsartan not superior to valsartan for advanced heart failure
(American College of Cardiology) Patients with heart failure with reduced ejection fraction (HFrEF) did not have better health outcomes if they took sacubitril/valsartan combination therapy compared with valsartan alone, according to new data presented at the American College of Cardiology's 70th Annual Scientific Session. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 17, 2021 Category: International Medicine & Public Health Source Type: news

PARADISE-MI Makes Me Question the Benefits of Sacubitril/Valsartan PARADISE-MI Makes Me Question the Benefits of Sacubitril/Valsartan
Sacubitril valsartan (Entresto), deemed'the Big E'by some clinicians, has fallen short in 2 of 3 clinical trials. The latest, presented at the ACC 2021 scientific session, is PARADISE-MI.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2021 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news

PARADISE-MI: Sacubitril/Valsartan Can ’t Beat Ramipril in Acute MI PARADISE-MI: Sacubitril/Valsartan Can ’t Beat Ramipril in Acute MI
Sacubitril/valsartan came suggestively close to showing efficacy for preventing cardiovascular death or heart failure events in patients with acute MI but no history of heart failure.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

Navigating Prior Authorization and Costs for HFrEF Drugs Navigating Prior Authorization and Costs for HFrEF Drugs
Online tools and decision aids can help clinicians and patients work through the barriers that have slowed the use of new drugs such as sacubitril-valsartan.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 11, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Feb 19 2021 This Week in Cardiology Feb 19 2021 This Week in Cardiology
Bernard Lown, Type 2 MI, Sacubitril/Valsartan and COVID19 anticoagulation are discussed in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 19, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news

FDA Expands Sacubitril/Valsartan Indication to Embrace Some HFpEF FDA Expands Sacubitril/Valsartan Indication to Embrace Some HFpEF
The newly approved labeling for sacubitril/valsartan (Entresto) is simply for"chronic heart failure" but almost teasingly adds,"the benefits are most clearly evident" at below-normal LVEF.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 17, 2021 Category: Cardiology Tags: Cardiology News Alert Source Type: news

Entresto Granted Expanded Indication in Chronic Heart Failure by FDA
EAST HANOVER, N.J., Feb. 16, 2021 -- Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 16, 2021 Category: Drugs & Pharmacology Source Type: news

Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF
The pricey drug Entresto is approved for heart failure with reduced ejection fraction, but should it also get an indication for HF with preserved ejection fraction? Cardiologist John Mandrola, MD, says no.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 15, 2021 Category: Cardiology Tags: Cardiology Expert Column Source Type: news

Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF
The pricey drug Entresto is approved for heart failure with reduced ejection fraction, but should it also get an indication for HF with preserved ejection fraction? Cardiologist John Mandrola, MD, says no.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 15, 2021 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news

Dec 18 2020 This Week in Cardiology Dec 18 2020 This Week in Cardiology
COVID, sacubitril/valsartan and spironolactone in patients with HFpEF, year-end comments are the topics discussed by John Mandrola, MD in this week ’s podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 18, 2020 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

FDA Panel Supports Expanded HF Role for Sacubitril/Valsartan FDA Panel Supports Expanded HF Role for Sacubitril/Valsartan
The advisors overwhelmingly favored an expanded indication, which they then narrowed to what guidelines call'mid-range LVEF.'But there was debate about what it should be called in labeling.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 16, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Sac/Val Heart Failure Benefit Extends to Diabetes Patients Sac/Val Heart Failure Benefit Extends to Diabetes Patients
The beneficial effects of sacubitril/valsartan on reverse cardiac remodeling in patients with heart failure and reduced ejection fraction extend to patients with type 2 diabetes, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 15, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

Sacubitril/Valsartan: Neprilysin Inhibition 5 Years Later Sacubitril/Valsartan: Neprilysin Inhibition 5 Years Later
In 2014, the PARADIGM-HF trial determined that sacubitril/valsartan improved outcomes compared to enalapril in patients with chronic HFrEF. What have we learned about neprilysin inhibition since?JACC: Heart Failure (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 4, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Updated ACC/AHA Heart Failure Measures Add Newer Meds Updated ACC/AHA Heart Failure Measures Add Newer Meds
Safety measures for lab monitoring of mineralocorticoid receptor agonist therapy, performance measures for sacubitril/valsartan, and cardiac resynchronization therapy are among the updates.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 3, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Entresto Halves Renal Events in Preserved EF Heart Failure Patients Entresto Halves Renal Events in Preserved EF Heart Failure Patients
The PARAGON-HF trial of sacubitril/valsartan in patients with heart failure with preserved ejection fraction didn't meet its primary outcome but significantly improved a secondary renal endpoint.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 14, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Empagliflozin's HFrEF Benefit Steady With Sacubitril/Valsartan Empagliflozin's HFrEF Benefit Steady With Sacubitril/Valsartan
The SGLT2 inhibitor empagliflozin works just as well when added on top of a second major agent used to treat patients with heart failure and reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 7, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Victory in HFpEF Again Evades ARNI Despite Hopeful Signals Victory in HFpEF Again Evades ARNI Despite Hopeful Signals
Close and yet so far: the ARNI sacubitril/valsartan, as it has done before, teased with post hoc signs of benefit in a preserved-EF heart failure, PARALLAX, without winning the primary endpoints.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 31, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

In-hospital Start of Sacubitril-Valsartan Cost-Effective in HFrEF In-hospital Start of Sacubitril-Valsartan Cost-Effective in HFrEF
Initiation of sacubitril-valsartan in acute HF is more clinically effective and cost-effective vs initiation in ambulatory HF. Full adoption of this strategy could save $92M yearly, researchers say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 18, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Ejection Fraction in Heart Failure Revisited Ejection Fraction in Heart Failure Revisited
A new study applied statistical methods to impute a historical placebo group to estimate the effects of sacubitril/valsartan in heart failure across the full range of LVEF.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 27, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Jul 10 2020 This Week in Cardiology Jul 10 2020 This Week in Cardiology
COVID, sacubitril/valsartan, left atrial appendage occlusion, and statins are the topics Dr John Mandrola discusses in this week ’ s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 10, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news

SAVE-ICD: For Some, Sacubitril/Valsartan May Obviate Need for ICD SAVE-ICD: For Some, Sacubitril/Valsartan May Obviate Need for ICD
For 1 in 4 heart failure patients, 6 months of sacubitril/valsartan was associated with a rise in LVEF to>35%, an observational study shows, raising the question of further need for ICD therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 4, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

HFpEF: Gender Difference in Sacubitril/Valsartan Response Remains Mystery HFpEF: Gender Difference in Sacubitril/Valsartan Response Remains Mystery
It remains unclear why women with heart failure with preserved ejection fraction, but not men, derive impressive clinical benefit from sacubitril/valsartan.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 20, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Population Impact of Generic Valsartan Recall Population Impact of Generic Valsartan Recall
How did the 2018 voluntary recall of 6 generic valsartan products impact prescribing patterns and outcomes for patients?Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 13, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Monitor BP in people routinely taking oral corticosteroids
Cumulative steroid dose associated with up to 30% increase in hypertension risk in people with chronic inflammatory diseases Related items fromOnMedica Withdrawn valsartan meds not linked to short-term cancer risk Pharmacists could offer high-dose statins direct to patients Too few women take part in many CVD clinical trials Statins safe and effective GPs defend practice on prescribing statins (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 23, 2020 Category: UK Health Source Type: news

Entresto (sacubitril and valsartan)
Title: Entresto (sacubitril and valsartan)Category: MedicationsCreated: 2/27/2020 12:00:00 AMLast Editorial Review: 2/27/2020 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - February 27, 2020 Category: Cardiology Source Type: news

Clinicians in the dark about potential harms of commonly prescribed beta blocker
Better understanding needed to stave off overdose deaths, warns HSIB Related items fromOnMedica Withdrawn valsartan meds not linked to short-term cancer risk Too few women take part in many CVD clinical trials Pharmacists could offer high-dose statins direct to patients Cannabinoids not recommended to treat cancer-related pain GPs defend practice on prescribing statins (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 18, 2020 Category: UK Health Source Type: news

Dec 6, 2019 This Week in Cardiology Dec 6, 2019 This Week in Cardiology
Vernakalent, CV death in cancer patients, dapagliflozin, and sacubitril/valsartan are the topics Dr. John Mandrola discusses in this week's podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 6, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Sun Pharma gets partial relief from US court in litigation involving three generic drugs
Drug major Sun Pharma is a defendant in a multi-district litigation brought by various classes of plaintiffs in the US District Court (District of Massachusetts), alleging a delay in the market entry for three generic drugs -- Valganciclovir, Valsartan and Esomeprazole. The company said it would continue to vigorously defend against all claims. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 1, 2019 Category: Pharmaceuticals Source Type: news

Making Room for New Drugs for Heart Failure Making Room for New Drugs for Heart Failure
Drs Ileana Pi ñ a and Mary Walsh discuss the latest HF updates from the American Heart Association Scientific Sessions and ask where dapagliflozin and sacubitril/valsartan will fit in the armamentarium.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 26, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Valsartan Recalls Took Toll on Patients' Health
WEDNESDAY, Nov. 20, 2019 -- Emergency room visits for high blood pressure surged following last year's recall of the popular heart drug valsartan, Canadian researchers report. Within the first month of the recall, there was a 55% increase of people... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 20, 2019 Category: General Medicine Source Type: news

Recalls of Blood Pressure Med Took Toll on Patients' Health
WEDNESDAY, Nov. 20, 2019 -- Emergency room visits for high blood pressure surged following last year's recall of the popular heart drug valsartan, Canadian researchers report. Within the first month of the recall, there was a 55% increase of people... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 20, 2019 Category: General Medicine Source Type: news

AHA: Impact of Valsartan Recall Examined for Ontario, Canada
MONDAY, Nov. 18, 2019 -- The generic valsartan recall has had population-level impacts on patients in Ontario, Canada, according to a research letter published online Nov. 11 in Circulation to coincide with the annual meeting of the American Heart... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 18, 2019 Category: Pharmaceuticals Source Type: news

Sacubitril/Valsartan Benefits Extend to HF With Mildly Reduced EF Sacubitril/Valsartan Benefits Extend to HF With Mildly Reduced EF
Further analysis of the PARAGON trial also suggest the benefit of the drug combination may reach higher ejection fractions in women.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 17, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Mylan hit with warning letter for valsartan manufacturing
The FDA sent a Mylan facility in India a warning letting for its manufacturing of APIs related to the widespread recall of blood pressure medications. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 13, 2019 Category: Pharmaceuticals Source Type: news

Generic Valsartan Abandoned After Recalls, ED Visits Rise Generic Valsartan Abandoned After Recalls, ED Visits Rise
Patients may have been willing to risk the short-term potential of uncontrolled hypertension to avoid ingesting a potential carcinogen in recalled generic valsartan medications, the authors say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 13, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

ER visits jumped after valsartan blood pressure medication recall, study says
After issuing a recall due to an impurity called NDMA, Health Canada urged patients not to stop taking their hypertension medications without consulting their health-care providers, but some may not have listened. (Source: CBC | Health)
Source: CBC | Health - November 12, 2019 Category: Consumer Health News Tags: News/Health Source Type: news

Aurobindo Pharma under USFDA scrutiny
Aurobindo has seen intense scrutiny on the manufacturer process of valsartan, an anti-hypertension drug, that was found to contain carcinogenic impurities. Apart from Aurobindo, those impurities were detected in several other batches manufactured by drug makers. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 4, 2019 Category: Pharmaceuticals Source Type: news

valsartan, Diovan
Title: valsartan, DiovanCategory: MedicationsCreated: 3/26/1998 12:00:00 AMLast Editorial Review: 10/17/2019 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - October 17, 2019 Category: Cardiology Source Type: news

Exercise essential for people diagnosed with cancer
Offer cancer patients tailored exercise prescription to protect their heart from damage, even before they start chemo Related items fromOnMedica Cancer patients using complementary meds die sooner Is crowdfunding for cancer patients paying for ‘quackery’? Exercise and psychological treatments cut cancer fatigue Withdrawn valsartan meds not linked to short-term cancer risk Cigars and pipes raise mortality risk independent of cigarettes (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 7, 2019 Category: UK Health Source Type: news

PROVE-HF Cracks the'Holy Grail' of Cardiac Remodeling in HFrEF PROVE-HF Cracks the'Holy Grail' of Cardiac Remodeling in HFrEF
Ileana Pi ñ a, MD speaks with lead author Jim Januzzi, MD, about the path to PROVE-HF and how sacubitril/valsartan benefits real-world patients with heart failure with reduced ejection fraction.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 7, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news

FDA Clears Sacubitril/Valsartan for Children With Heart Failure FDA Clears Sacubitril/Valsartan for Children With Heart Failure
Sacubitril/valsartan is approved to treat symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients 1 year and older.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 3, 2019 Category: Cardiology Tags: Cardiology News Alert Source Type: news

FDA Approves Entresto (sacubitril/valsartan) for Pediatric Heart Failure
East Hanover, N.J., Oct. 1, 2019– Novartis announced today that the U.S. Food and Drug Administration (FDA) has approved Entresto (sacubitril/valsartan) for the treatment of symptomatic heart failure (HF) with systemic left ventricular... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 1, 2019 Category: Drugs & Pharmacology Source Type: news

CVS Pulls Zantac And Similar Heartburn Drugs Over Cancer Concerns
(CNN) — CVS Pharmacy has stopped selling Zantac, as well as its generic version of the heartburn medication, over concerns that they might contain a substance that could cause cancer. CVS, the largest pharmacy chain in the country, said over the weekend it was suspending sale of Zantac and other products which contain ranitidine until further notice. The US Food and Drug Administration said earlier this month that it has learned that some ranitidine — acid-reducing and heartburn medicines, including those known by the brand name Zantac — contain low levels of an impurity that could cause cancer. Zantac an...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 30, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Featured Health News Syndicated CBSN Boston CVS Zantac Source Type: news

Rosemarie Riddell Bogdan, Esq. Appointed to Plaintiffs ’ Steering...
Martin, Harding & Mazzotti, LLP Partner Rosemarie Riddell Bogdan appointed to a leadership position on the Plaintiffs’ Personal Injury Steering Committee in National Valsartan NDMA contamination...(PRWeb September 25, 2019)Read the full story at https://www.prweb.com/releases/rosemarie_riddell_bogdan_esq_appointed_to_plaintiffs_steering_committee_in_national_valsartan_ndma_products_liability_litigation/prweb16596119.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 25, 2019 Category: Pharmaceuticals Source Type: news

FDA Expands Recall Of Blood Pressure Drugs Again
(CNN) — Torrent Pharmaceuticals Ltd. has expanded its voluntary recall of two blood pressure medications after trace amounts of a potentially cancer-causing impurity were found during testing. The recall affects Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets. Tests of some of those medications revealed amounts of N-methylnitrosobutyric acid (NMBA) that were above the US Food and Drug Administration’s daily acceptable levels. This recall is related to the valsartan recall that has been expanded multiple times since July, when separate lots of blood pressure medications from dif...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 24, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston CNN Recall Valsartan Source Type: news

Novartis Stops Distributing Generic Zantac Over Potential Cancer-Causing Ingredient
WASHINGTON (CBS) – Drug maker Novartis has halted distribution of generic versions of Zantac. The popular heartburn medication has been investigated for containing a potential cancer-causing ingredient. A Novartis spokesman told CBS News “our internal investigation is ongoing to determine further details,” and the drug can remain on pharmacy shelves for now. Sanofi, the French pharmaceutical company that makes Zantac, said it had no plans to stop distribution or production. Last week, the FDA said that ranitidine treatments like Zantac have been found to contain a “probable” carcinogenic impur...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Consumer Health News Syndicated CBSN Boston FDA Zantac Source Type: news

Questions raised over quality of trials supporting new cancer drugs approvals
Potential risk of bias in half of trials supporting new cancer drug approvals in Europe, study suggests Related items fromOnMedica Only half of new cancer drugs extend or improve life Drugs regulators “put profits before patients” Doctors debate long-term use of psychiatric drugs Withdrawn valsartan meds not linked to short-term cancer risk We must revise drug regulatory framework at EU and national levels (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 18, 2019 Category: UK Health Source Type: news